ABSTRACT
Cannabis is the world's most popular illicit drug, and around half of all Danes have tried it at least once. In this paper we review the pharmacodynamic and pharmacokinetic properties of cannabis. We also discuss the treatment of cannabis intoxication and present data from The Danish Poison Information Center.
Subject(s)
Cannabinoids , Cannabis , Age Distribution , Cannabinoids/adverse effects , Cannabinoids/pharmacology , Cannabinoids/poisoning , Cannabis/adverse effects , Cannabis/poisoning , Denmark , Drug Interactions , Humans , Illicit Drugs/adverse effects , Illicit Drugs/pharmacology , Illicit Drugs/poisoning , Marijuana Abuse/diagnosis , Marijuana Abuse/drug therapy , Marijuana Abuse/prevention & control , Marijuana Abuse/psychology , Poison Control Centers , Substance Withdrawal Syndrome/drug therapyABSTRACT
Synthetic "designer drugs" with hallucinogenic properties have become increasingly popular among recreational drug users in recent years. Some of the designer drugs are chemically modified drugs previously used in treatment of depression and chronic fatigue. The drugs are available from a large number of internet distributers. There is very little knowledge of the clinical symptoms and how intoxicated people should be treated. We present a review of published literature (including 284 intoxicated patients) and experiences from the Danish poison centre concerning two chemical derivatives of earlier registered drugs.
Subject(s)
Alkaloids/pharmacology , Benzodioxoles/pharmacology , Central Nervous System Stimulants/pharmacology , Designer Drugs/pharmacology , Pyrrolidines/pharmacology , Tryptamines/pharmacology , Alkaloids/administration & dosage , Alkaloids/poisoning , Benzodioxoles/administration & dosage , Benzodioxoles/poisoning , Central Nervous System Stimulants/administration & dosage , Central Nervous System Stimulants/poisoning , Chronic Disease , Depression/drug therapy , Designer Drugs/administration & dosage , Designer Drugs/poisoning , Fatigue/drug therapy , Hallucinogens/administration & dosage , Hallucinogens/pharmacology , Hallucinogens/poisoning , Humans , Monoamine Oxidase Inhibitors/administration & dosage , Monoamine Oxidase Inhibitors/pharmacology , Monoamine Oxidase Inhibitors/poisoning , Poison Control Centers , Pyrrolidines/administration & dosage , Pyrrolidines/poisoning , Tryptamines/administration & dosage , Tryptamines/poisoning , Synthetic CathinoneABSTRACT
Bromo-Dragonfly (BDF) is a designer drug chemically related to LSD and amphetamine. The first registration in Denmark was in October 2007. In the present case an 18-year-old man ingested about 2 ml BDF and developed acute psychosis. At the hospital the patient displayed, hyperpyrexia, tachycardia, tachypnea and hypertension. Because of severe hallucinations and agitation the patient was detained at the hospital and received symptomatic treatment with large doses of benzodiazepines. Four days after hospitalization, the patient discharged himself without significant symptoms or paraclinical findings.
